Preliminary evaluation of concurrent radiochemotherapy plus pucotenlimab in adult high-grade gliomas: a single-institution retrospective observational study
High-grade gliomas (HGGs) are WHO grade Ⅲ - Ⅳ malignant brain tumors associated with a dismal prognosis. Despite the availability of multimodal treatment approaches, the 5-year survival rate remains < 5%, underscoring the urgent need for novel therapeutic strategies to improve outcomes in this aggressive disease....